Ventyx Biosciences reported Phase II data for oral NLRP3 inhibitor VTX‑3232 showing rapid, large reductions in high‑sensitivity C‑reactive protein (hsCRP) and other cardiovascular inflammation biomarkers. In a placebo‑controlled mid‑stage trial of patients with obesity and cardiovascular risk factors, monotherapy produced a near‑term hsCRP reduction of roughly 78% and achieved multiple secondary biomarker improvements, while combination with semaglutide lowered liver inflammation measures in patients with baseline steatosis. The safety and tolerability profile met primary objectives and the biomarker outcomes have spurred business development interest; MedCity News and other outlets reported that the readout has catalyzed talks with larger pharmas regarding partnership or licensing. Ventyx’s shares surged following the announcement, reflecting investor optimism for an oral NLRP3 approach across cardiometabolic and neuroinflammatory indications. Translational questions remain: whether biomarker improvements will translate into hard cardiovascular outcomes and which patient subsets will benefit most. Still, the data add to a growing body of clinical evidence supporting NLRP3 as a therapeutic axis and increase the appeal of oral anti‑inflammasome drugs to strategic partners.